pdufa.bio

S-303 Treated

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET

S-303 Treated is a Cerus Corp program. Every date links its source.

CERS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Cerus Corp (CERS). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Apr 2026CERS

Specialist biotech funds holding CERS, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors6,395,431$18.7 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is S-303 Treated's next FDA decision or readout?

No upcoming catalyst is on our calendar for S-303 Treated; no FDA decisions are on record below.

What happened at S-303 Treated's most recent FDA decision?

No FDA decision for S-303 Treated is in our archive yet.

Who makes S-303 Treated?

Cerus Corp (CERS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.